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a b s t r a c t
Background: Launched in 1974, the Expanded Program on Immunization (EPI) is estimated to prevent
two-three million deaths annually from polio, diphtheria, tuberculosis, pertussis, measles, and tetanus.
Additional lives could be saved through better understanding what influences adherence to the EPI
schedule in specific settings.
Methods: The Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the
Consequences for Child Health and Development (MAL-ED) study followed cohorts in eight sites in
South Asia, Africa, and South America and monitored vaccine receipt over the first two years of life for
the children enrolled in the study. Vaccination histories were obtained monthly from vaccination cards,
local clinic records and/or caregiver reports. Vaccination histories were compared against the prescribed
EPI schedules for each country, and coverage rates were examined in relation to the timing of vaccination.
The influence of socioeconomic factors on vaccine timing and coverage was also considered.
Results: Coverage rates for EPI vaccines varied between sites and by type of vaccine; overall, coverage
was highest in the Nepal and Bangladesh sites and lowest in the Tanzania and Brazil sites. Bacillus
Calmette-Guérin coverage was high across all sites, 87–100%, whereas measles vaccination rates ranged
widely, 73–100%. Significant delays between the scheduled administration age and actual vaccination
date were present in all sites, especially for measles vaccine where less than 40% were administered

Abbreviations: MAL-ED, The Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development; EPI,
Expanded Program on Immunization; BGD, Dhaka, Bangladesh; BRF, Fortaleza, Brazil; INV, Vellore, India; NEB, Bhaktapur, Nepal; PEL, Loreto, Peru; PKN, Naushero Feroze,
Pakistan; SAV, Venda, South Africa; TZH, Haydom, Tanzania; BCG, Bacillus Calmette-Guérin; DPT, Diphtheria, Pertussis, and Tetanus; OPV, Oral Polio Vaccine; IPV, Inactivated
Polio Vaccine; LTF, lost to follow up; WAMI, Water/sanitation, Assets, Maternal education and Income; DHS, Demographic Health Survey; WHO, World Health Organization;
UNICEF, United Nations Children’s Fund.
⇑ Corresponding author at: Division of International Epidemiology and Population Studies of Fogarty International Center, National Institutes of Health, 16 Center Drive,
Building 16, Room 202, Bethesda, MD 20892, USA.
E-mail address: christel.host@nih.gov (C. Hoest).
1
MAL-ED Network Investigators (see supplementary material for complete list).
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0264-410X/Ó 2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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on schedule. A range of socioeconomic factors were significantly associated with vaccination status in
study children but these results were largely site-specific.
Conclusions: Our findings highlight the need to improve measles vaccination rates and reduce delayed
vaccination to achieve EPI targets related to the establishment of herd immunity and reduction in disease
transmission.
Ó 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).

1. Introduction
The Expanded Program on Immunization (EPI) was established
to ensure that all children have access to and receive basic immunizations [1]. Vaccination schedules are designed to balance maximizing vaccine efficacy (i.e. targeting the ages for optimal
immunological response) with high population coverage (i.e. leveraging frequent contacts with healthcare providers during the first
months of life) to achieve high levels of vaccine effectiveness [2].
The EPI prevents an estimated two to three million child deaths
annually; however, despite near global adoption of EPI recommendations, schedules and vaccination rates vary greatly by country.
Steady increases in global vaccination rates since 1990 [3] suggest
that the overall EPI target, that 90% of children in the world should
be vaccinated with Bacillus Calmette-Guérin (BCG), 3rd dose of
Diphtheria, Pertussis, and Tetanus (DPT3), 1st dose of measles vaccine (MCV1), and 3rd dose of Oral Polio Vaccine (OPV3) by 2020, is
within reach [4]. This progress can be accelerated and significant
disease burden reduced by better understanding the factors associated with vaccine coverage and timeliness. However, few studies
have addressed the extent of delayed vaccination across multiple
regions of the world [5,6].
The Etiology, Risk Factors and Interactions of Enteric Infections
and Malnutrition and the Consequences for Child Health and
Development (MAL-ED) Study is a multi-site cohort study
investigating the effects of undernutrition, gut function, and
enteric disease on child development, growth, and vaccine
response [7]. Children in the MAL-ED cohorts, located in Dhaka,
Bangladesh (BGD), Fortaleza, Brazil (BRF), Vellore, India (INV),
Bhaktapur, Nepal (NEB), Loreto, Peru (PEL), Naushero Feroze, Pakistan (PKN), Venda, South Africa (SAV), and Haydom, Tanzania
(TZH), were followed for the first two years of life providing an
opportunity to assess adherence to national EPI schedules in
diverse settings [8–15]. Here we describe vaccination coverage in
the MAL-ED cohorts and examine adherence to country-specific
EPI schedules. Additionally, we evaluate how socioeconomic and
demographic factors are associated with vaccination and schedule
adherence.

tered during home visits on the monthly anniversary of the child’s
birth (±2 days) to collect information on vaccine receipt. The
mother/caregiver was asked to provide information on vaccinations since the previous visit, using the vaccine card issued by
the health provider when possible or based on mother/caregiver
recollection if no vaccine card was available. Additionally, a quarterly vaccine information form recorded vaccines received and
date of administration based on the child’s vaccination card if present, clinical records or mother/caregiver’s best recollection; the
source of the vaccination history was also noted and the records
were furthermore used to confirm data from the monthly questionnaire. Approval to access health records of study children for
vaccination information was received from local Internal Review
Board. Extensive quality control activities were coordinated uniformly across all sites in real time. Vaccinations occurring outside
the expected site-specific EPI schedule and vaccinations inconsistently reported on the two forms (monthly and quarterly) were
reported back to the sites where study personnel made appropriate
corrections after confirming the information with the source.
2.3. Analytical methods

Country-specific EPI schedules and vaccine information were
collected by study personnel. For several countries, the EPI schedule was modified during the study period of 2009–2014; changes
were accounted for where appropriate. Additionally, vaccine campaigns conducted throughout the study period were documented.

Children with P12 months of follow-up were included in the
primary analysis. Depending on the country-specific schedule,
regardless of vaccination age, children were considered fully vaccinated at 12 months of age with a minimum of 1 dose of BCG, 3
doses of DPT, 1 dose of measles vaccine, and 3–5 doses of Oral/
Inactivated Polio Vaccine (OPV/IPV). For schedule adherence analyses, vaccinations were considered ‘on time’ if administered within
7 days of the scheduled time (14-day window). Per EPI recommendations, for vaccines with multiple doses, the scheduled interval
between initial and subsequent doses was considered more important than the specific age at receipt of subsequent doses if the initial dose was off schedule. To assess bias in the sample due to drop
outs, the proportion of children who adhered to the schedule prior
to being lost to follow up (LTF) was estimated.
Student’s t-tests and tests to compare two proportions were
used to compare fully vaccinated versus non-fully vaccinated children for overall socioeconomic status (the Water/sanitation,
Assets, Maternal education and Income [WAMI] index) [17], and
factors including household income in US dollars, maternal age,
years of maternal education, number of siblings in the household,
sex, whether the child was first born, and place of delivery. Proportions tests were used to examine timeliness of vaccination; age at
the first dose of BCG, DPT, OPV, or measles were indicators for
schedule adherence. p-Values equal to or below 0.10 were considered significant. All analyses were performed using STATA version
13 (StataCorp LP. College Station, TX).

2.2. Child vaccination histories

3. Results

Data collection methods have been previously described [16].
Briefly, the MAL-ED cohorts consisted of approximately 200
children per site followed from birth to 24 months of age [7]. The
study was observational and vaccines were not administered by
the study. A structured vaccine history questionnaire was adminis-

The MAL-ED cohorts were selected to represent a broad range of
low and middle income country settings including a mix of urban
and rural locations where malnutrition and enteric disease burden
were high [8–15]. The median monthly household income across
all sites was $113 (range $0–1648/month) ranging from $14 in

2. Methods
2.1. EPI schedule
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TZH to $347 in BRF and the median maternal age was 26 years
(range 14–49 years) while the median maternal education was
7 years (range 0–20 years) (Supplementary Table 1).

3.1. EPI schedule
Country-specific EPI schedules varied between sites (Table 1).
DPT, Hepatitis B (HepB), and Haemophilus influenzae type b
(Hib) vaccine were administered simultaneously in a pentavalent
formulation in most MAL-ED sites. In BRF, during the early study
period, tetravalent vaccine (DPT + Hib) was used with HepB
administered separately before pentavalent vaccine introduction
in July 2012. In INV, Hib vaccine was introduced with the switch
to pentavalent vaccine in December 2011. In SAV, the pentavalent
vaccine utilized contained DPT, Hib, and IPV with HepB administered separately. In PEL, HepB was given at birth before later
administration of pentavalent vaccine. SAV was the only site using
a combined OPV/IPV schedule in their polio vaccine program,
which was introduced in 2009 [18].
Substantial heterogeneity between the design and infrastructure of vaccine delivery systems was observed (Table 2). Sites
offered all EPI vaccines free of charge at local hospitals or health
clinics, with the cost covered by government or nongovernmental organizations. The timing and frequency of vaccine
availability was variable between sites and vaccines and may have
influenced timeliness of administration. However, in all sites
except for BRF and SAV, all vaccines were offered at least weekly.
Community-wide vaccine campaigns occurred in all sites. OPV
was the most frequent component of campaigns, which occurred
in all sites except Tanzania. Pakistan and India frequently
employed this strategy with 29 and 10 campaigns recorded during
the study period, respectively. Children received up to 19 doses in
PKN and up to 11 doses in INV by age 24 months (Supplementary
Fig. 1).

3.2. MAL-ED vaccine coverage
The primary source of vaccine histories was vaccination cards;
80% of DPT1 records were obtained from vaccine cards, 6% were
verbal caregiver records, while 12% came from clinical records.
There were differences between the sites in vaccination history
sources; 100% of vaccination histories in BGD, BRF, and NEB were
obtained from vaccine cards compared to 5% in PKN; where the
majority of information (83%) came from clinical records.
Vaccination rates varied greatly by site and vaccine (Table 3 and
Supplementary Table 2). NEB had complete coverage for all vaccines. The low 15% coverage rate in TZH was driven by OPV; 22%
of children were fully vaccinated against polio whereas other vaccines reached >70%. BGD had homogeneously high coverage for all
vaccines in contrast to BRF where close to 100% of children
received BCG while only 73% received measles vaccine. Sites using
pentavalent vaccine throughout the study period reached coverage
ranging from 73% in TZH, 89% in PKN, 96% in BGD, to 100% in NEB.
Hib vaccine was introduced in INV after most of the cohort had
surpassed appropriate vaccination age resulting in only 20% coverage. The global EPI target of fully vaccinated rates of >90% for all
children, was reached in only two sites (BGD and NEB), though
many individual vaccines had coverage levels >90% at most sites.
Within the MAL-ED cohort, 75% of all children were fully vaccinated by age 24 months. Children LTF before 12 months of age
had lower vaccine coverage than children meeting the inclusion
criteria (Supplementary Table 3).

3.3. EPI schedule adherence
Administration of vaccines was delayed at all sites to a variable
degree (Fig. 1). BCG is scheduled at birth, and the majority received
the vaccine on time, the median was 4 days ranging from 1 day in
NEB, PEL, and SAV to 38 days in TZH. The medians for DPT1 and

Table 1
EPI vaccine schedule for selected vaccines in MAL-ED countries. Several changes to the schedules occurred throughout the study period; the schedule reflects the schedule at the
end of data collection period. BCG: Bacillus Calmette-Guiren; OPV: Oral Polio Vaccine; IPV: Inactivated Polio Vaccine; DPT: Diphtheria, Pertussis, Tetanus; HEPB: Hepatitis B; Hib:
Heaemophilus influenzae type b; w: weeks; m: months.
Vaccine/# doses

Bangladesh
BGD

BCG

Birth

Birth

Birth

Birth

Birth

Birth

Birth

Birth

OPV1
OPV2
OPV3
OPV4
OPV5

6w
10w
14w
9m

2m
4m
6m
15m

Birth
6w
10w
14w
16–24m

6w
10w
14w

2m
4m
6m

Birth
6w
10w
14w

Birth
6w

Birth
1m
2m
3m

IPV1
IPV2
IPV3
IPV4
DPT1
DPT2
DPT3
DPT4

a

Brazil
BRF

India
INV

Nepal
NEB

Peru
PEL

Pakistan
PKN

South Africa
SAV

6w
10w
14w
18m
6w
10w
14w
18m

Tanzania
TZH

6w
10w
14w

2m
4m
6m
15m

6w
10w
14w
16–24m

6w
10w
14w

2m
4m
6m
18m

6w
10w
14w

HEPB1
HEPB2
HEPB3
HEPB4

6w
10w
14w

Birth

6w
10w
14w

6w
10w
14w

Birth
2m
4m
6m

6w
10w
14w

6w
10w
14w

1m
2m
3m

Hib1
Hib2
Hib3
Hib4

6w
10w
14w

2m
4m
6m

6w
10w
14w

6w
10w
14w

2m
4m
6m
18m

6w
10w
14w

6w
10w
14w
18m

1m
2m
3m

Measles1
Measles2

9m
15–18m

12m
15m

9–12m
(12–15m)

9m
(15m)a

12m

9m
15m

9m
18m

9m

1m
6m

Optional with payment. Optional vaccines in parentheses.

1m
2m
3m
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Table 2
Source, schedule, distribution, and availability of vaccines by site. Information collected from the site personnel. BGD: Dhaka, Bangladesh; BRF: Fortaleza, Brazil; INV: Vellore,
India; NEB: Bhaktapur, Nepal; PEL: Loreto, Peru; PKN: Naushero Feroze, Pakistan; SAV: Venda, South Africa; TZH: Haydom, Tanzania.
BGD

BRF

INV

PEL

PKN

SAV

TZH

Distributors of
vaccine

Public and NGOs

Public

Public and private Public and
private

NEB

Public

Public

Government
outsource to
private
companies

Public

Location of
distribution

NGO based
community
outposts; public
hospitals

Public health
centers; public
hospitals

Local hospitals
Primary Health
and health
Centers; health
clinics and mobile centers
units run by the
Govt.

Public
Hospitals,
Health
Centers, and
Health Posts
(not private
clinics)

Primary health centers
and public hospitals

Health clinics
and hospitals

Local
hospitals
and health
clinics

Schedule for
distribution

Public hospitals
run vaccination
activities
throughout the
year

Beginning of
each month

3 days a week at
Vaccines are
administered on a the local
hospital and
scheduled day
vaccination
every week; 4
clinics on
times a month
Saturdays in
one community

All days
except
Sundays, from
around 7am to
1 pm. 1 day a
week to
distribute a
particular
vaccine

Measles and BCG
available once a week,
other vaccines available
all days except Sunday
from 9 am to 2 pm

Every two
weeks

Daily in
hospitals
and health
clinics and
monthly in
mobile
clinics

Availability of
vaccination

Widely available

Widely
available, when
limited
prioritization by
age, younger to
older

Widely available,
restrictions based
on geography and
location

Widely
available

Widely available
throughout the
community and year
around

Widely
available

Widely
available

Cost to families

All EPI vaccines
are free

All EPI vaccines All EPI vaccine are All EPI vaccines All EPI
are free
free
are free
vaccines are
free

All EPI vaccines are free

All EPI
vaccines are
free

All EPI
vaccines
are free

Vaccine campaigns

4 or more each
year through inter
agency Coordination
Committee
meeting. They use
all types of media
for campaigning

Campaigns are
national and is
programmed by
the ministry of
health.
Requested by a
municipal can
be made

Pulse Polio
campaigns are
held by the Govt.
twice a year in
January &
February, where
OPV is
administered to
all <5 years

No specific
campaigns for
EPI regular
vaccines. OPV
campaigns are
offered through
mobile
vaccination
clinics

Few
campaigns run
from the
health centers
free of cost to
the familiesa

OPV national
immunization days twice
a year. Supplementary
vaccination days
frequently throughout
the year. Measles and
Tetanus campaign
through special
initiatives

Campaigns are
organized by
mobile clinics
and specific
locations like
schools and
local Chiefs’
kraals

Few
campaigns
run from
mobile
units. Free
of cost

No. Vaccine
campaigns

7 OPV
1 MEA

7 OPV

10 OPV

11 OPV
1 MEA

2 OPV
1 DPT

29 OPVb
3 MEA

4 OPV
4 MEA

1 MEA
All
Vaccinesc

Widely
available
through
hospitals and
clinics

1 MMR
a

This is done when a vaccine lot is near expiration, about once a year. The health post nurses are paid extra to go from house to house looking for children <5 years; if they
are unable to show record of vaccination, eligible children are vaccinated.
b
PKN information only up to August 2013.
c
TZH had a campaign to cover all vaccines in April 2013.

OPV1 were 5.56 and 4 days, respectively. Age at measles vaccination ranged broadly with the majority administered within 60 days
of the scheduled date with a median of 16 days ranging from
10.5 days in SAV to 36 days in INV. Adherence to the EPI schedule
varied considerably between sites and vaccines (Fig. 2). Generally,
BCG was more likely to be given on time, although there was significant site-to-site variability (14% in TZH and 94% in SAV).
DPT1 was administered on time in >50% of children in BGD, BRF,
NEB, PEL, and SAV compared to 23% in TZH. A similar pattern
emerged in the timing of OPV1 ranging from 12% in TZH to 95%
in SAV but with PKN and TZH as the only sites with <50% adherence. Measles vaccine had low schedule adherence in most sites
ranging from 12% of children in TZH to 39% in BGD and PEL. In
INV, measles vaccine was administered on time in 74% of children;
however instead of a fixed vaccination time, India has a window
from 9 to 12 months hence a larger window for ‘on time’ vaccination. In most cases when an initial vaccine was delayed, successive
doses were then appropriately adjusted to maintain EPIrecommended intervals between doses (data not shown).

3.4. Influence of socioeconomic factors on vaccination status and
schedule adherence
Associations between socioeconomic factors and achievement
of complete and on-time vaccination were largely site-specific.
The exception was birth setting, which was associated with the
likelihood of a child being fully vaccinated and/or the likelihood
of vaccine schedule adherence in every site except SAV (Table 4).
The majority of study children were born in a hospital (private or
public) or health clinic and only 3 sites had >10% of children born
in the home; in PKN, TZH, and BGD 59%, 50%, and 30% of children
were born at home, respectively. In TZH, only 4% of children born
at home received the BCG and OPV at birth whereas 24% and 20%
of the children born in a hospital facility received it on time,
respectively. In PKN and BGD, only 85% of children born at home
were fully vaccinated compared to 92% and 97%, respectively of
the children born at a health facility. In INV, fully-vaccinated children were more likely to live in households with fewer other children, more highly-educated mothers and higher WAMI scores,
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Table 3
Number of children enrolled, number of children with 12 months of follow-up (%), and percent of children vaccinated fully according to schedule by age 12 months (95%
confidence intervals). Fully vaccinated ALL includes BCG, DPT, OPV/IPV, and measles. BGD: Dhaka, Bangladesh; BRF: Fortaleza, Brazil; INV: Vellore, India; NEB: Bhaktapur, Nepal;
PEL: Loreto, Peru; PKN: Naushero Feroze, Pakistan; SAV: Venda, South Africa; TZH: Haydom, Tanzania.
Enrolled

P12m
follow-up
(%)

Complete
vaccination
BCG

Complete
vaccination
DPT

Complete
vaccination
OPV/IPV

Complete
vaccination
Measles

Fully
vaccinated
ALL

Complete
vaccination
HepB

Complete
vaccination
Hib

BGD

265

231
(87)

100

96.1
(93.6–98.6)

97.8
(95.9–99.7)

96.5
(94.2–98.9)

93.9
(90.8–97.0)

96.1
(93.6–98.6)

96.1
(93.6–98.6)

BRF

233

194
(83)

100

75.3
(69.1–81.4)

86.1
(81.2–91.0)

73.2
(66.9–79.5)

59.3
(52.3–66.2)

77.8
(71.9–83.7)

75.3
(69.1–81.4)

INV

251

229
(91)

99.1
(97.9–100.3)

82.5
(77.6–87.5)

91.7
(88.1–95.3)

86
(81.5–90.5)

78.2
(72.8–83.6)

72
(66.2–77.9)

19.6
(14.5–24.8)

NEB

240

231
(96)

100

100

100

100

100

100

100

PEL

303

244
(80)

98.8
(97.4–100.2)

96.7
(94.5–99.0)

97.1
(95.0–99.2)

90.2
(86.4–93.9)

86.1
(81.7–90.4)

90.2
(86.4–93.9)

96.7
(94.5–99.0)

PKN

277

256
(92)

98.8
(97.5–100.1)

89
(85.2–92.9)

100

99.6
(98.8–100.4)

88.3
(84.3–92.2)

89.1
(85.2–92.9)

89.1
(85.2–92.9)

SAV

314

253
(81)

96.8
(94.7–99.0)

82.6
(77.9–87.3)

78.3
(73.1–83.4)

89.3
(85.5–93.2)

72.7
(67.2–78.2)

87.3
(83.2–91.5)

82.6
(77.9–87.3)

TZH

262

233
(89)

87.1
(82.8–91.5)

72.1
(66.3–77.9)

21.9
(16.5–27.2)

76.4
(70.9–81.9)

15.4
(10.8–20.1)

72.1
(66.3–77.9)

72.1
(66.3–77.9)

Total

2145

1871
(87)

97.5
(96.8–98.2)

87.1
(85.5–88.6)

84.2
(82.6–85.9)

89.4
(88.0–90.8)

74.7
(72.7–76.7)

85.8
(84.2–87.4)

79.4
(77.5–81.2)

Percent of all children

40

20

BCG

30

15

20

10

10

5

0

0

20

40

60

80

100

30

120

140

160

180
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Fig. 1. Schedule adherence. Number of days between scheduled and actual vaccination day for the first dose of BCG, DPT, OPV, and measles for all children. BCG1: first dose of
BCG; DPT1: first dose of DPT; Measles1: first dose of measles.

than their non-fully vaccinated counterparts (Table 5). More years
of maternal education and higher WAMI index were significantly
associated with full vaccination in PKN. Maternal age and household income were not significantly associated with complete vac-

cination in any site; however, higher household income tended
to associate with full vaccination.
In INV, fewer total children in the household, higher maternal
education, and higher WAMI index were associated with greater
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4. Discussion

Fig. 2. Schedule adherence by vaccine. Percent children vaccinated on schedule
(within 7 days of the EPI scheduled date) by vaccine by site. BCG1: first dose of BCG;
DPT1: first dose of DPT; Measles1: first dose of measles; BGD: Dhaka, Bangladesh;
BRF: Fortaleza, Brazil; INV: Vellore, India; BGD: Bhaktapur, Nepal; PEL: Loreto, Peru;
PKN: Naushero Feroze, Pakistan; SAV: Venda, South Africa; TZH: Haydom, Tanzania.

vaccine schedule adherence while in other sites few of these relationships were present (Supplementary Table 4). Sex was inconsistently associated with vaccination rates and schedule adherence:
in PKN, females were more likely to receive measles vaccine on
time and in BGD, females were more likely to receive BCG on time.
In INV, first born children were more likely to be fully vaccinated
and to receive measles vaccine on time (Supplementary Table 5).

The MAL-ED study included intensive, prospective surveillance
of vaccinations obtained from local health sources in eight communities, creating an opportunity for detailed analysis of vaccine coverage and timeliness under circumstances resembling real-world
conditions [7]. Measles coverage was lowest among the vaccines
analyzed in this study with only three sites having rates above
the 95% required for development of herd immunity. This low coverage is concerning as measles incidence has been increasing
worldwide in recent years [19]. Globally, coverage is 84%, well
below the threshold to stop transmission, as is the overall 89% coverage in MAL-ED and in TZH, where coverage is low at 76% we saw
a measles outbreak during 2012 with 68 cases admitted to the hospital. These low rates suggest the goal of measles elimination is
likely to remain elusive without enhanced efforts to improve
measles vaccine coverage [20]. Recent experimental and epidemiological studies [21,22] provide complementary evidence that
measles infection reduces population immunity to other infectious
diseases for up to three years. The persistence of low measles vaccine coverage represents a missed opportunity to not only prevent
mortality and morbidity from measles, but also other childhood
infections.
All MAL-ED sites participated in vaccine campaigns. Six sites
utilized measles vaccine campaigns; the two sites not doing so
were those with the lowest coverage, BRF and INV, suggesting that
measles campaigns might help boost overall coverage. Although,
TZH did have a measles campaign, increases in vaccination during
this period did not occur—suggesting that more promotion is necessary to fully realize the mop-up potential of a campaign. Polio
campaigns were most frequent and utilized extensively in Pakistan
and India where polio is still a concern. Consequently, children in
these sites received a large number of extra doses. A study in India
found that the intense focus on polio eradication did not adversely

Table 4
Comparison of proportions (95% confidence intervals) of children born in the hospital or in the home by MAL-ED site with regards to schedule adherence and full vaccination
status. Hospital includes public and private hospital and health clinics. BCG1: first dose of BCG; DPT1: first dose of DPT; Measles1: first dose of measles; fully vaccinated: received
P1 BCG, P3 DPT, P3–5 Polio, and P1 measles; BGD: Dhaka, Bangladesh; BRF: Fortaleza, Brazil; INV: Vellore, India; NEB: Bhaktapur, Nepal; PEL: Loreto, Peru; PKN: Naushero
Feroze, Pakistan; SAV: Venda, South Africa; TZH: Haydom, Tanzania.

a

Place of birth

N

BCG1 On time

DPT1 On time

OPV1 On time

Fully vaccinated

BGD

Hospital
Home
P-value

159
69

0.23 (0.17–0.30)
0.30 (0.20–0.41)
0.25

0.63 (0.55–0.70)
0.72 (0.62–0.83)
0.16

0.57 (0.50–0.65)
0.67 (0.56–0.78)
0.18

0.97 (0.95–1.00)
0.85 (0.77–0.94)
<0.01

BRF

Hospital
Home
P-value

185
5

0.63 (0.56–0.70)
0.60 (0.17–1.03)
0.88

0.57 (0.50–0.64)
0.00
0.01

0.52 (0.45–0.60)
0.00
0.02

0.61 (0.54–0.68)
0.20 ( 0.15 to 0.55)
0.06

INV

Hospital
Home
P-value

222
6

0.53 (0.46–0.59)
0.50 (0.10–0.90)
0.90

0.44 (0.38–0.51)
0.17 ( 0.13 to 0.46)
0.18

0.53 (0.47–0.90)
0.50 (0.10–0.90)
0.88

0.79 (0.73–0.84)
0.50 (0.10–0.90)
0.09

NEB

Hospital
Home
P-value

225
6

0.80 (0.74–0.85)
0.00
<0.01

0.76 (0.70–0.82)
0.33 ( 0.04 to 0.71)
0.02

0.70 (0.64–0.76)
0.33 ( 0.04 to 0.71)
0.05

a

PEL

Hospital
Home
P-value

230
14

0.90 (0.87–0.94)
0.50 (0.24–0.76)
<0.01

0.86 (0.81–0.90)
0.79 (0.57–1.00)
0.47

0.85 (0.81–0.90)
0.79 (0.57–1.00)
0.50

0.86 (0.82–0.91)
0.86 (0.67–1.04)
0.97

PKN

Hospital
Home
P-value

106
150

0.46 (0.37–0.56)
0.42 (0.34–0.50)
0.50

0.27 (0.19–0.36)
0.27 (0.20–0.34)
1.00

0.38 (0.28–0.47)
0.39 (0.31–0.47)
0.80

0.92 (0.87–0.97)
0.85 (0.80–0.91)
0.08

SAV

Hospital
Home
P-value

220
2

0.94 (0.91–0.97)
1.00
0.72

0.71 (0.65–0.77)
1.00
0.37

0.95 (0.92–0.98)
1.00
0.75

0.73 (0.67–0.79)
1.00
0.39

TZH

Hospital
Home
P-value

117
116

0.24 (0.16–0.32)
0.04 (0.01–0.08)
<0.01

0.21 (0.14–0.29)
0.24 (0.16–0.32)
0.61

0.20 (0.12–0.27)
0.04 (0.01–0.08)
<0.01

0.16 (0.10–0.23)
0.15 (0.08–0.21)
0.74

All children in NEB were fully vaccinated. Bold numbers indicate a significant finding: p-value <0.10.
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Table 5
Socioeconomic characteristics for fully (+Full Vax) and not-fully (-Full Vax) vaccinated children (fully vaccinated defined as P 1 BCG,P3 DPT,P3–5Polio, and P 1 Measles doses)
analyzed by comparison of the proportions (95% confidence intervals) of children fully or not fully vaccinated. BGD: Dhaka, Bangladesh; BRF: Fortaleza, Brazil; INV: Vellore, India;
NEB: Bhaktapur, Nepal; PEL: Loreto, Peru; PKN: Naushero Feroze, Pakistan; SAV: Venda, South Africa; TZH: Haydom, Tanzania.
t-test

Na

Number of children
in household

Maternal age

Years of maternal
education

WAMI

Household income
($US dollars)

BGD

Full Vax
+Full Vax
P-value

13–14
204–217

2.15 (1.46–2.84)
1.91 (1.76–2.05)
0.41

24.2 (21.0–27.4)
25.0 (24.3–25.6)
0.60

4.5 (2.8–6.2)
4.6 (4.2–5.0)
0.89

0.55 (0.47–0.63)
0.53 (0.51–0.54)
0.62

131 (95–168)
127 (113–141)
0.89

BRF

Full Vax
+Full Vax
P-value

79
115

2.48 (2.13–2.83)
2.23 (1.99–2.47)
0.21

25.4 (24.3–26.5)
25.7 (24.6–26.8)
0.71

9.3 (8.7–9.8)
8.9 (8.4–9.5)
0.40

0.82 (0.8–0.84)
0.82 (0.9–0.84)
0.92

343 (311–375)
360 (333–387)
0.42

INV

Full Vax
+Full Vax
P-value
Full Vax
+Full Vax
P-value

49–50
175–176

2.69 (2.22–3.17)
2.00 (1.83–2.17)
<0.01
–

25.2 (23.8–26.6)
24.2 (23.6–24.8)
0.13
–

5.8 (4.7–6.9)
7.2 (6.7–7.4)
0.02
–

0.38 (0.34–0.42)
0.47 (0.45–0.49)
<0.01
–

71 (60–83)
77 (69–84)
0.49
–

NEBb

a
b

0
231

PEL

Full Vax
+Full Vax
P-value

34
209–210

2.47 (1.83–3.11)
2.43 (2.20–2.65)
0.88

23.9 (21.7–26.0)
24.8 (24.0–25.6)
0.42

7.2 (6.2–8.2)
7.8 (7.4–8.1)
0.30

0.51 (0.45–0.56)
0.54 (0.53–0.56)
0.13

137 (104–169)
138 (128–148)
0.91

PKN

Full Vax
+Full Vax
P-value

30
225–226

3.43 (2.64–4.23)
3.22 (2.94–3.49)
0.60

28.6 (26.6–30.6)
28.5 (27.7–29.3)
0.93

1.7 (0.6–2.8)
3.3 (2.7–3.8)
0.04

0.41 (0.34–0.47)
0.50 (0.47–0.52)
0.01

141 (101–181)
181 (162–199)
0.14

SAV

Full Vax
+Full Vax
P-value

53–69
126–184

2.70 (2.23–3.16)
2.26 (2.04–2.49)
0.06

27.9 (25.9–30.0)
27.6 (26.4–28.9)
0.81

9.9 (9.4–10.5)
10.2 (9.9–10.4)
0.36

0.73 (0.69–0.77)
0.76 (0.74–0.78)
0.124

223 (182–263)
263 (219–307)
0.27

TZH

Full Vax
+Full Vax
P-value

191–195
36

4.03 (3.69–4.37)
4.03 (3.18–4.87)
0.99

29.4 (28.5–30.3)
29.9 (27.6–32.3)
0.66

5.1 (4.7–5.5)
4.9 (3.9–5.8)
0.62

0.21 (0.20–0.23)
0.19 (0.15–0.23)
0.25

27 (23–32)
36 (18–54)
0.18

N varies between variables analyzed.
All children in NEB were fully vaccinated. Bold numbers indicate a significant finding: p-value <0.10.

affect coverage for other routine vaccinations; instead, DPT3 coverage increased between 2008 and 2011 [23]. Similarly, vaccine coverage in the PKN and INV sites did not suffer compared to coverage
in other MAL-ED cohorts. The absence of OPV campaigns in MALED’s TZH cohort and the extremely low 22% coverage rate suggest
that routine administration of OPV (and the planned 2016 introduction of the OPV-IPV combination) may need to be enhanced
by campaign efforts to sufficiently support conditions for global
polio eradication [24]. Generally, the positive effect of campaigns
related to vaccine coverage rates suggests that these campaigns
effectively boosted immunization rates and are a useful tool to
reach the EPI target of 90% coverage. Similarly, more campaigns
offering multiple EPI vaccines would increase the accessibility of
all vaccines.
The MAL-ED study obtained information on vaccination history
from a variety of sources. The coverage data primarily came from
vaccination cards but there was heterogeneity in information
sources within and between sites. The low retention of vaccination
cards found in PKN was consistent with previous findings in Pakistan [25]. A recent review of the reliability of vaccine data found
that data from vaccine cards likely underestimate true coverage
whereas data from recall and medical provider sources tend to
be overestimates [26]. However, based on frequent surveillance
and communication with site personnel, we consider the MAL-ED
estimates robust.
Compared to country-specific coverage rates found by the
Demographic Health Survey (DHS), World Health Organization
(WHO) and United Nations Children’s Fund (UNICEF), for
individual EPI vaccines the MAL-ED cohort rates were higher for
all sites except Tanzania where coverage was lower across all vaccines (Supplementary Table 6). According to WHO/UNICEF estimates, four of the countries containing MAL-ED sites had
coverage >90% for DPT, OPV, and measles; whereas estimates were
lower than 90% in South Africa, India, Peru, and Pakistan [27]. The

WHO/UNICEF estimates are primarily based on administrative data
from vaccination service providers while DHS are a cross-sectional
view of vaccine coverage making a direct comparison unreliable.
Despite this study finding mostly higher coverage rates than
national estimates, it is worth noting that concerns remain about
the overestimation of vaccine coverage in countries where immunization funding relies on a performance-based system. The discrepancies between such findings emphasize the need for higher
quality and more systematic monitoring of such indicators to better inform and improve global vaccination efforts [28].
For many low resource countries, the convenience of the EPI
schedule is as important as timeliness of vaccination for development of herd immunity and for reduction in disease burden [6].
In the MAL-ED cohort, BCG coverage was highest with >97% in 7
sites. BCG was also most likely to be administered on schedule, largely due to the fact that it is given at birth. When delivery occurs in
a health facility, the child is easily accessible for on-time vaccine
administration. In 3 sites there were significant differences in the
timeliness of BCG administration depending on birth location. In
TZH, timeliness of BCG was low in hospitals as well as home births
and that could be attributed to problems with supply. However, we
did not see large gaps in the vaccination date and since many children did not receive the vaccine until 1, 2 or 3 months of age there
are likely other reasons in play as well. Later vaccines require the
caregiver to bring the child to immunization facilities, increasing
the risk of a delayed or missed appointment. Measles vaccine
was most likely to be delayed, possibly because it is given later
in life (9–12 months of age) and often given as the only vaccination
at that time. This was also shown in a South African study where
timeliness and coverage were lower for later vaccinations and in
poorer populations [29]. In NEB, where coverage was 100% for all
vaccines but timeliness was suboptimal, the delay was attributed
to a variety of reasons including: less focus on timely vaccination
as opposed to getting vaccinated, the frequent travel necessary to
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accommodate the EPI schedule, and a tendency for parents to postpone vaccination during mild illness or discomfort of the child.
Similarly, the low coverage and timeliness in TZH was attributed
in part to rural surroundings of the TZH field site, along with lack
of communication between health facilities and the population.
These are areas that could be improved with increased focus on
communication from the vaccine providers and educational materials to the population regarding the importance of getting vaccinations and getting them on schedule. In addition to examining a ±7day window around the scheduled day as a marker for timeliness,
we also tested a ±14-day window for sensitivity (data not shown).
We decided to use the ±7-day window, as the broader window did
not change the associations found and therefore would not help to
improve the estimates of timeliness.
We evaluated correlations between socioeconomic and demographic factors and coverage and schedule adherence; the diversity
of findings between sites reflects the culture- and countrydependent nature of the SES factors measured. A high percentage
of cohort children had high coverage for individual vaccines but
in the sites with the lowest coverage, TZH and BRF, there were
no factors that stood out as associated with lower coverage. A
Brazilian study found that birth order and higher household
income were associated with higher risk of incomplete vaccination
[30]. Although we were not able to confirm those results we did
find that being a first born child was a predictor for on time vaccination with BCG and DPT. A Tanzanian study found that maternal
education was associated with not being vaccinated while poverty
and maternal education were associated with delayed vaccination
[31]. None of these relationships were seen in the MAL-ED cohort,
however the small sample size and similar poverty level throughout the cohort could explain the lack of associations. Lastly, indications from several of the MAL-ED sites suggest that travel distance
to health clinics and frequency were inhibitory for timely and complete vaccination status, however we were not able to investigate
this further in this study.

development of herd immunity and disease transmission; the continued occurrence of measles outbreaks likely results from such
subpar timeliness and coverage and prolongs needless mortality
and morbidity from measles and other childhood infections. The
diversity between sites suggests that country-specific interventions are needed to meet EPI targets and better measure target
indicators.

4.1. Limitations

Appendix A. Supplementary material

We examined vaccine coverage in children age 0–24 months;
this observation period may lead to an underestimate of the total
vaccination coverage in the life of a child. A study of vaccine coverage in low- and middle-income countries found increased coverage when including children up to age 36 months allowing for late
catch-up vaccination. Measles vaccine coverage increased from
54% at 12 months to 82% at 36 months indicating that many children were vaccinated at older ages [6]. Children LTF before
12 months of age had lower vaccine coverage while under observation compared to children remaining in the study beyond
12 months. This could lead to a potential overestimation of the
vaccine coverage in the cohort while also indicating that our study
population might have higher vaccination rates and adherence
compared to the general population. Furthermore, the intensive
surveillance could have influenced coverage as caregivers may
have been more likely to pursue vaccination; however, we found
that only 2 sites reached the EPI target of >90% coverage for all vaccines among all cohort children.

Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.vaccine.2016.11.
075.

5. Conclusion
Childhood vaccinations are an essential public health tool to
prevent serious disease in young children and optimal effectiveness requires vaccine administration according to the EPI schedule.
We found that despite high vaccine coverage in most MAL-ED sites,
vaccine administration was frequently delayed, especially measles
vaccine. Delayed vaccination has consequences for the
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